KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer

The purpose of this study is to evaluate the efficacy and safety of KC1036 in combination with PD-1 antibody and platinum-based chemotherapy as a first-line treatment for patients with unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC).

Trial Details

NCT ID
NCT07481058
Phase
PHASE2
Sponsor
Beijing Konruns Pharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
Squamous Cell Esophageal Cancer
Interventions
  • KC1036
  • Toripalimab
  • Paclitaxel
  • Cisplatin
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Males or females aged 18 to 75 years;
  • Histologically or cytologically confirmed esophageal or esophageal-gastric junction squamous cell carcinoma;
  • Patients who have not received prior systemic anti-tumor therapy for the current recurrent or metastatic disease;
  • At least one measurable tumor lesion according to RECIST 1.1;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Squamous Cell Esophageal Cancer Trials on Trialify →